Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as “an extensive pipeline of ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...

Erste Group analysts upgraded Eli Lilly stock from Hold to Buy, citing a robust product demand and a promising pipeline of potential successes. The analysts highlighted the pharmaceutical company's ...

We recently compiled a list of the 12 Best Big Name Stocks to Invest in Now. In this article, we are going to take a look at ...

I think Eli Lilly and Company's stock correction may ... I see from indirect signs that the overall demand for LLY's key products — Zepbound and Mounjaro — keeps rising in the US.

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus. Here's why they view Eli Lilly (NYSE ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, ...